This suggests afatinib is a drug active against wild-type EGFR. The third-generation EGFR TKI, osimertinib, has been approved for patients with T790M-positive NSCLC with acquired resistance to EGFR TKIs. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.